aibio.space Financings Desk
Equity raises: follow-on and public offerings, PIPEs and private placements, registered directs, ATM programs, shelf registrations, warrant deals and royalty or licence money of $5 million or more.
Sources: SEC filings and company press releases, with wires, trade press and court dockets used as leads and confirmed against a filing. The desk follows our editorial standards. 709 stories so far.
Latest stories
- INmune Bio raises $4.50 million in registered direct offering with warrants
- Lexeo Therapeutics files $300 million shelf registration
- ProKidney files $650 million shelf with $200 million Jefferies sales program
- Actuate Therapeutics prices $11.0 million offering of shares and warrants
- Adial Pharmaceuticals renames itself Azora Therapeutics after preferred stock vote
- Silexion files to register resale of up to 8,813,531 shares
- Aclaris Therapeutics prices $49,999,934 stock and pre-funded warrant offering
- Endovia Health Sciences raises equity line ceiling to $135 million
- Imunon files for share offering with 350% warrant coverage in four tranches
- Rapport Therapeutics launches stock offering and convertible notes due 2032
- Valion Bio sells preferred stock, mostly to settle overdue Series C payments
- Acumen Pharmaceuticals files a $500,000,000 shelf registration
- First EQ504 dosing unlocks a $20 million private placement tranche for Equillium
- Traws Pharma signs $50,000,000 stock purchase agreement with Roth Principal Investments
- United Therapeutics authorizes another $2 billion share repurchase
- Sagimet expects cash and $115 million offering to fund operations to mid-2029
- Arcus raises $250 million at $17.50 a share a day after kidney cancer data
- China SXT ends purchasers' right to buy up to $12 million more shares
- Disc Medicine raises $450 million at $75 a share after phase 3 win
- Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross
- BioAtla signs $40.0 million standby equity deal with Yorkville
- Indaptus Therapeutics closes $24.0 million private placement of 20,338,974 shares
- Surrozen closes $95.1 million second tranche of March 2025 private placement
- Alpha Teknova launches stock offering, then prices 8,000,000 shares at $5.00
- Curis agrees to sell stock and warrants for about $8.5 million in gross proceeds
- Dogwood Therapeutics agrees to sell $5 million of stock to top holder CK Life Sciences
- OS Therapies gets $7.2 million gross from initial warrant inducement closing
- Tenon Medical obtains investor waiver to increase at-the-market sales
- Alector prices $75,030,000 stock offering at $2.05, above prior close
- Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants
- Recursion raises $200 million at $3.25 a share as Sanofi options first candidate
- ALX Oncology swaps 13,353,384 shares for pre-funded warrants with investors
- Evofem Biosciences pushes Adjuvant note maturity to December 1, 2026
- First Tracks Biotherapeutics agrees to sell 6,106,870 shares at $32.75, about $200 million
- Ultragenyx agrees to transfer two priority review vouchers for $413 million
- Silo Pharma issues 150,000 shares to buy software and intellectual property
- Vir Biotechnology agrees to sell Gilead 1,765,486 shares for about $25 million
- Vaxcyte raises about $1.1 billion in stock and convertible notes after phase 3 win
- AquaBounty to convert all preferred stock into 8,077,043 common shares
- Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share
aibio